Trials / Unknown
UnknownNCT02441972
Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
Phase 1 Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Wuxi No. 4 People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine whether 18F-Al labeled RGD is safety and effective for cancer diagnosis and therapy response.
Detailed description
Observe radiation dose to healthy volunteers and patients; the correlation between integrin level and tumor/metastases uptake.
Conditions
- Tumors
- Carcinoma, Bronchogenic
- Breast Carcinoma
- Cancer of Head and Neck
- Lymphoma, Malignant
- Soft Tissue Neoplasms
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F-Al-NOTA-PRGD2 PET/CT | 18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min. |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
- First posted
- 2015-05-12
- Last updated
- 2017-03-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02441972. Inclusion in this directory is not an endorsement.